We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Peak Pharmaceuticals Inc (PK) | USOTC:PKPH | OTCMarkets | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 1.55 | 1.56 | 2.59 | 0.00 | 01:00:00 |
|
(a)
|
The
reasons described in reasonable detail in Part III of this form
could not be eliminated without unreasonable effort or
expense;
|
☒
|
(b)
|
The
subject annual report, semi-annual report, transition report on
Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or
portion thereof, will be filed on or before the fifteenth calendar
day following the prescribed due date; or the subject quarterly
report or transition report on Form 10-Q or subject distribution
report on Form 10-D, or portion thereof, will be filed on or before
the fifth calendar day following the prescribed due date;
and
|
|
(c)
|
The
accountant's statement or other exhibit required by Rule 12b-25(c)
has been attached if applicable.
|
Neil
Reithinger
|
|
480
|
|
659-6404
|
(Name)
|
|
(Area
Code)
|
|
(Telephone
Number)
|
|
|
|
|
Date
February 15, 2018
|
By:
|
/s/
Neil
Reithinger
|
|
|
Name: Neil
Reithinger
|
|
|
|
Title: Chief Executive Officer |
|
1 Year Peak Pharmaceuticals (PK) Chart |
1 Month Peak Pharmaceuticals (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions